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Abstract 
Purpose:  To evaluate the prognostic effect of central obesity on triple negative breast cancer (TNBC).
Methods: 206 TNBC patients treated from June 2006 to June 2015 were enrolled retrospectively. Body mass index 
(BMI) ≥25 kg/m2 was the standard of obesity and waist circumference ≥80 cm was the standard of central obesity. 
Patient and tumor characteristics were compared between obesity categories. Survival differences between obesity 
categories were assessed with log‑rank test in the univariate analysis and prognostic factors were then investigated by 
Cox regression analysis.
Results: 81 cases were with obesity (39.3 %). 71 cases were with central obesity (34.5 %). Patients with obesity or 
central obesity tended to be older (P = 0.022 for obesity; P = 0.013 for central obesity) and to have larger tumor size 
(P = 0.027 for obesity; P = 0.027 for central obesity). By Cox regression analysis, central obesity (DFS: HR 1.759; 95 % 
CI 1.009–3.065; P = 0.046. OS: HR 2.297; 95 % CI 1.184–4.456; P = 0.014) was identified as an independent prognos‑
tic factor. For central obesity with BMI ≥ 25 kg/m2, the prognostic effect was more apparent (DFS: HR 1.845; 95 % CI 
1.059–3.212; P = 0.031. OS: HR 2.377; 95 % CI 1.230–4.593; P = 0.010).
Conclusion: Central obesity, especially with high BMI, was an independent prognostic factor for TNBC.
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Background
Triple negative breast cancer (TNBC) is defined by the 
absence of estrogen receptor (ER), progesterone recep-
tor (PR), and human epidermal growth factor receptor-2 
(HER-2) overexpression, which accounts for 15–20 % of 
breast cancer patients (Perou et al. 2000). It is character-
ized by occurrence at young age and a high propensity 
of early metastasis to distant visceral organs (Chen and 
Ding 2015). Women with TNBC have worse prognos-
tic outcomes compared with those with other subtypes 
(Dent et al. 2007). Given the lack of targeted therapy and 
limited treatment options, researchers have paid much 
attention on some modifiable factors associated with the 
prognosis of TNBC.
Obesity is now a common health problem worldwide. 
It is a lifestyle risk factor associated with not only high 
risk of cardiovascular and metabolic disease, but also 
with high incidence and poor prognosis of many malig-
nant tumors (Ryan and Kushner 2010; Renehan et  al. 
2008). A growing body of literature indicates that metab-
olism syndrome is related closely with the development 
and progression of TNBC (Davis and Kaklamani 2012; 
Maiti et  al. 2010). Obesity, especially central obesity 
plays a central role in metabolism syndrome. It is well 
acknowledged that obesity is associated with a worse 
clinical outcome in breast cancer patients (Kroenke et al. 
2005; Petrelli et  al. 2002; Loi et  al. 2005; Abrahamson 
et al. 2006). But most researches included breast cancer 
cases of all subtypes or only cases with positive hormone 
receptors. Limited researches have evaluated the associa-
tions of obesity at diagnosis on TNBC prognosis, and the 
findings are mixed (Ademuyiwa et al. 2011; Sparano et al. 
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2012; Mowad et al. 2013; Tait et al. 2014; Dawood et al. 
2012; Turkoz et al. 2013; Hao et al. 2015). Meanwhile as 
far as our knowledge, there is no literature specifically 
focused on the significance of central obesity among 
TNBC patients.
Purpose
The purpose of this study is to retrospectively investigate 
the effects of central obesity at the time of breast cancer 
diagnosis on recurrence and mortality among women 
with TNBC who were treated at our hospital.
Methods
Patients
We retrospectively enrolled 206 TNBC patients who were 
treated at the Department of Breast Surgery of Obstet-
rics and Gynecology Hospital of Fudan University from 
June 2006 to June 2015. The status of the estrogen recep-
tor (ER), progesterone receptor (PR), and human epider-
mal growth factor receptor-2 (HER-2) was determined 
by immunohistochemical (IHC) staining. TNBC was 
defined by ER positivity and PR positivity less than 1 % 
of tumor cells with positive nuclear staining and HER-2 
status (−) or (1+) by IHC or lack of gene amplification 
confirmed by florescent in situ hybridization (FISH).
This study was approved and exempted from patient 
permission by Institutional Review Boards. All patients 
received standard treatment, including mastectomy or 
breast-conserving surgery (BCS) plus axillary lymph 
node dissection (ALND)/sentinel lymph node biopsy 
(SLNB), adjuvant/neoadjuvant chemotherapy composed 
of anthracyclines and/or taxanes followed by radiother-
apy (if required). All patients with positive lymph node 
metastasis received ALND. Patients were excluded for 
the following reasons: male gender, in  situ lesion, cura-
tive resection not conducted, and distant metastasis con-
firmed before surgery.
Obesity standards
We identified body mass index (BMI)  ≥25  kg/m2 
as the standard of obesity and waist circumference 
(WC)  ≥  80  cm for women as the standard of central 
obesity according to the recommendation of the inter-
national diabetics federation. BMI is computed by divid-
ing the weight in kilograms by the square of the height in 
meters.
Follow‑up
Overall survival (OS) was calculated as the time from 
diagnosis to death or last follow-up and disease-free sur-
vival (DFS) was calculated as the time from diagnosis to 
first recurrence/metastasis or last follow-up. Those with-
out any evidence of relapse were censored at the last date 
on which they were known to be alive. Patients who were 
lost to follow-up were censored at the date of their last 
follow-up. All recurrences were diagnosed by either clini-
cal or radiological examinations. Follow-up information 
regarding tumor relapse and survival status was available 
through outpatient departmental records and personal 
contact with the patients via mail and telephone calls 
until Jan 2016.
Statistics
Patient and tumor characteristics were compared 
between obesity categories using an independent sam-
ple t test for continuous variables and the Pearson Chi 
square test for categorical variables. Fisher’s exact test 
was used when needed. The Kaplan–Meier method was 
used to generate survival curves and differences between 
obesity categories were assessed with the log-rank test. 
All variables with statistical significance in the univari-
ate analysis were investigated by multivariate analysis to 
compare survival outcomes among obesity categories. 
Adjusted hazard ratios (HR) with 95 % confidence inter-
vals (95  % CI) were calculated using Cox proportional 
hazards model. All the statistical analysis was performed 
using SPSS 19.0 software package (SPSS, Chicago, IL, 
USA). Two-sided P  <  0.05 was considered statistically 
significant.
Results
Baseline information and patient characteristics by obesity 
categories
206 patients with AJCC stage I to III TNBC who had 
baseline weight and height recorded were identified. 
The median age for the entire cohort was 48.5  years 
(range 27–73  years). BMI ranged from 18.7 to 31.1  kg/
m2 (median 23.8  kg/m2). According to the standard of 
obesity as BMI ≥  25  kg/m2, 81 cases were with obesity 
(39.3  %) and according to the standard of central obe-
sity as WC ≥ 80 cm, 71 cases were with central obesity 
(34.5 %). Among the 71 cases, 23 cases had diabetics, 32 
cases had hypertension, and 25 cases had hyperlipidemia. 
It was observed that among TNBC patients with central 
obesity, 67 cases had their BMI ≥ 25 kg/m2. The other 4 
cases with central obesity but BMI < 25 kg/m2 were rela-
tively tall and had no such metabolic diseases.
The majority of the study population who received 
adjuvant/neoadjuvant chemotherapy received an anthra-
cycline-based regimen (96.1 %); doxorubicin plus cyclo-
phosphamide followed by a taxane was the most frequent 
regimen administered.
Distributions of patient characteristics by obesity cat-
egories were tabulated in Table 1. Patients with obesity or 
central obesity tended to be older (BMI ≥ 25 kg/m2: 51.8 
vs 48.5 years, P = 0.022; WC ≥ 80 cm: 52.3 vs 48.5 years, 
Page 3 of 8Chen et al. SpringerPlus  (2016) 5:594 
P = 0.013), and to have larger tumor size (BMI ≥ 25 kg/
m2: 3.34 vs 2.71  cm, P  =  0.027; WC  ≥  80  cm: 3.38 vs 
2.73  cm, P  =  0.027) and higher proportion of pT2 and 
pT3 stage (BMI  ≥  25  kg/m2: P  =  0.031; WC  ≥  80  cm: 
P  =  0.044). There was no significant difference among 
obesity or central obesity groups with regard to meno-
pausal status, histologic grade, pN stage, lymphovascular 
invasion (LVI), and surgery type.
Survival prognosis analysis of obesity on TNBC
During the median follow-up of 59  months (range 
6–106  months) after diagnosis, 38 deaths and 52 recur-
rences were documented among 206 TNBC patients 
included in this analysis. Three cases (1.5 %) were lost to 
follow-up in the third year after diagnosis, who were nei-
ther with obesity nor central obesity.
In univariate analysis of prognostic factors by log-
rank test, LVI (DFS: log-rank χ2 = 16.864, P < 0.001; OS: 
log-rank χ2  =  10.896, P  =  0.001), pT stage (DFS: log-
rank χ2 =  15.201, P =  0.001; OS: log-rank χ2 =  17.619, 
P  <  0.001), pN stage (DFS: log-rank χ2  =  32.551, 
P  <  0.001; OS: log-rank χ2  =  33.476, P  <  0.001), obe-
sity (DFS: log-rank χ2 =  3.945, P =  0.047; OS: log-rank 
χ2 = 4.113, P = 0.043) and central obesity (DFS: log-rank 
χ2 = 3.931, P = 0.047; OS: log-rank χ2 = 4.987, P = 0.026) 
were significantly predictive of recurrence and survival 
outcome.
Figures  1, 2 illustrated the Kaplan–Meier survival 
curves of obesity categories (obesity, central obesity and 
central obesity with BMI ≥ 25 kg/m2). The separation of 
survival curves were most apparent among central obe-
sity with BMI  ≥  25  kg/m2 (DFS: log-rank χ2  =  5.627, 
P = 0.018; OS: log-rank χ2 = 6.710, P = 0.010).
A Cox regression analysis including the possible prog-
nostic factors above identified pT stage, pN stage, LVI 
and central obesity (DFS: HR 1.759; 95  % CI 1.009–
3.065; P  =  0.046. OS: HR 2.297; 95  % CI 1.184–4.456; 
P = 0.014.) rather than general obesity (DFS: P = 0.125; 
OS: P = 0.059) as independent prognostic factors for DFS 
and OS of TNBC. For central obesity with BMI ≥ 25 kg/
m2, the prognostic effect was more apparent (DFS: HR 
1.845; 95  % CI 1.059–3.212; P  =  0.031. OS: HR 2.377; 
95 % CI 1.230–4.593; P = 0.010.) (Table 2).
Discussion
Obesity is becoming more and more popular all over the 
world. According to a recent report, the world has tran-
sitioned from one in which underweight prevalence was 
more than double that of obesity, to one in which more 
people are obese than underweight. In 2014 there were 
Table 1 Clinico-pathological characteristics of TNBC patients among obesity categories
Obesity Central obesity
BMI ≥ 25 kg/m2 (%) BMI < 25 kg/m2 (%) P WC ≥ 80 cm (%) WC < 80 cm (%) P
Menopausal status 0.130 0.245
 Pre‑menopausal 40 (49.4) 73 (58.4) 35 (49.3) 78 (57.8)
 Post‑menopausal 41 (50.6) 52 (41.6) 36 (50.7) 57 (42.2)
pT stage 0.031 0.044
 pT1 21 (25.9) 55 (44.0) 18 (25.4) 58 (43.0)
 pT2 52 (64.2) 60 (48.0) 46 (64.8) 66 (48.9)
 pT3 8 (9.9) 10 (8.0) 7 (9.9) 11 (8.1)
pN stage 0.446 0.987
 pN0 43 (53.1) 78 (62.4) 41 (57.7) 80 (59.3)
 pN1 21 (25.9) 29 (23.2) 17 (23.9) 33 (24.4)
 pN2 14 (17.3) 13 (10.4) 10 (14.1) 17 (12.6)
 pN3 3 (3.7) 5 (4.0) 3 (4.2) 5 (3.7)
LVI 0.623 0.140
 Positive 29 (35.8) 49 (39.2) 22 (31.0) 56 (41.5)
 Negative 52 (64.2) 76 (60.8) 49 (69.0) 79 (58.5)
Histologic grade 0.864 0.658
 Median 56 (69.1) 85 (68.0) 50 (70.4) 91 (67.4)
 Low 25 (30.9) 40 (32.0) 21 (29.6) 44 (32.6)
Surgery 0.468 0.578
 Mastectomy 71 (87.7) 105 (84.0) 62 (87.3) 114 (84.4)
 BCS 10 (12.3) 20 (16.0) 9 (12.7) 21 (15.6)
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triple obese men and twice obese women than 40 years 
ago (NCD Risk Factor Collaboration (NCD-RisC) 2016). 
The current status of obesity prevalence among Chinese 
women is also concerning. In 2014, China had the most 
obese women in the world (46.4 million), accounting for 
12.4  % of global obesity (NCD-RisC 2016). A survey in 
2015 showed 45.3  % Chinese women were with obesity 
or overweight (BMI ≥  24  kg/m2), among whom 44.6  % 
were with central obesity (Wang et al. 2015). In our study, 
39.3  % cases were with obesity and 34.5  % cases were 
with central obesity, which closely mirrored recent trends 
in the Chinese population.
At the same time, the incidence of breast cancer is ris-
ing rapidly in China in recent years. Breast cancer was 
the most commonly diagnosed cancer among Chinese 
women in 2015, accounting for 15  % of all new cancers 
Fig. 1 Survival curves of TNBC according to obesity categories. a DFS curves according to BMI. b OS curves according to BMI. c DFS curves accord‑
ing to WC. d OS curves according to WC
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in women (Chen et al. 2016). And breast cancer cases in 
China account for 12.2  % of all newly diagnosed breast 
cancers and 9.6 % of all deaths from breast cancer world-
wide (Fan et al. 2014). Through a combination of multi-
disciplinary management, the incorporation of newer 
and more efficacious chemotherapeutic and biological 
therapies and implementation of aggressive supportive 
care services, the prognostic outcome of women with 
breast cancer has improved over the decades. Women 
with TNBC continue to have worse prognostic outcomes 
compared with those with non-TNBC (Dent et al. 2007). 
Researchers have focused on the mechanisms of TNBC 
progression and potential targets for therapy. Obesity is a 
modifiable lifestyle risk factor that has been shown to be 
associated with increased risk of developing breast can-
cer including TNBC (Phipps et  al. 2011), and is known 
to predict for the development of distant metastases and 
breast cancer-related deaths (Ewertz et al. 2011). So it is 
of great importance to evaluate the impact of obesity on 
the clinical outcome of TNBC.
Our study showed that obese TNBC tended to be older 
and to have larger tumor mass, which was in accord with 
most literature (Ewertz et  al. 2011; Deglise et  al. 2010). 
Probably patients with obesity might have difficulty in 
touching a small lesion in relatively large breast, leading 
to a larger tumor mass when diagnosed. Deglise et  al. 
(2010) pointed out that infiltrating tumor lesion less than 
1  cm was more likely to be impalpable in patients with 
obesity. It was also reported that post-menopausal TNBC 
were more frequently observed in patients with obesity 
(Ewertz et al. 2011; Deglise et al. 2010), which was incon-
sistent with our study, probably due to not enough post-
menopausal cases in our study. Meanwhile our study 
failed to find the association between obesity and histo-
logic grade, pN stage and LVI of TNBC. The association 
between obesity and breast cancer characteristics above 
was also inconsistent among the results from various lit-
eratures (Loi et al. 2005; Eichholzer et al. 2013).
A substantial body of evidence exists linking obesity to 
prognostic outcome among women with breast cancer 
(Protani et al. 2010; Azrad and Demark-Wahnefried 2014; 
Chan et  al. 2014). A systematic review that included 82 
follow-up breast cancer studies showed that obesity was 
associated with poorer overall and breast cancer survival 
both in pre-menopausal and post-menopausal breast 
cancer (Chan et al. 2014).
But only limited research has evaluated the associa-
tions of obesity on TNBC prognosis, and the findings 
are mixed (Ademuyiwa et  al. 2011; Sparano et  al. 2012; 
Mowad et al. 2013; Tait et al. 2014; Dawood et al. 2012; 
Turkoz et al. 2013; Hao et al. 2015). Sparano et al. (2012) 
observed obesity not to be significantly associated with 
an inferior prognostic outcome among women with 
TNBC. The largest retrospective study including 2311 
women with stage I-III TNBC tumors found no dif-
ference in DFS or OS across BMI groups at diagnosis 
(Dawood et  al. 2012). Similar null association between 
BMI at diagnosis and TNBC survival was also observed 
Fig. 2 Survival curves of TNBC according to BMI + WC. a DFS curves according to BMI + WC. b OS curves according to BMI + WC
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in two retrospective studies of TNBC patients (Ademuy-
iwa et al. 2011; Tait et al. 2014). While Turkoz et al. (2013) 
confirmed the relationship between obesity and poorer 
prognostic outcome of TNBC. And a study on Chinese 
women also drew a conclusion that BMI ≥ 24 kg/m2 was 
a negative prognostic factor of TNBC (Hao et al. 2015).
The difference in the study design, the characteristics of 
study population, duration of follow-up or cut-off value 
of BMI assessment may be partly contributed to the dis-
crepancy. Most research defined obesity as BMI ≥ 30 kg/
m2 according to the World Health Organization guide-
line, which was based on the body size characteristics 
of western country population. This standard did not fit 
for Chinese population. As a growing body of evidence 
suggested a strong link between metabolic syndrome 
and breast cancer, BMI  ≥  25  kg/m2 as obesity stand-
ard by international diabetics federation was adopted in 
our study. It could be observed that a large proportion 
of TNBC patients with central obesity in our study had 
some kinds of cardiovascular or metabolic disease.
Our study was the first to specifically evaluate the 
prognostic outcome effect of central obesity on TNBC. 
It was concluded that BMI ≥ 25 kg/m2 was not an inde-
pendent prognostic factor of TNBC although it was of 
statistical significance in univariate analysis. But central 
obesity was the independent prognostic factor of TNBC, 
and the effect was even more apparent in central obesity 
with BMI ≥ 25 kg/m2. Probably WC may mistake some 
Table 2 multivariate analysis of TNBC prognostic factors by Cox regression model
DFS OS
P HR 95.0 % CI P HR 95.0 % CI
Model 1: BMI ≥ 25 kg/m2 as a covariate into Cox regression model
 LVI: positive versus negative 0.012 2.165 1.182–3.965 0.045 2.075 1.017–4.237
 pT stage 0.045 0.033
 pT2 versus pT1 0.037 2.228 1.049–4.736 0.055 2.476 0.981–6.247
 pT3 versus pT1 0.020 3.417 1.217–9.593 0.010 4.672 1.453–15.021
 pN stage 0.018 0.048
 pN1 versus pN0 0.004 2.862 1.410–5.809 0.050 2.304 0.999–5.318
 pN2 versus pN0 0.008 3.016 1.331–6.831 0.009 3.460 1.370–8.736
 pN3 versus pN0 0.108 2.642 0.808–8.636 0.051 3.797 0.993–14.525
 BMI: BMI ≥ 25 kg/m2 versus BMI < 25 kg/m2 0.125 1.554 0.885–2.728 0.059 1.904 0.976–3.713
Model 2: WC ≥ 80 cm as a covariate into Cox regression model
 LVI: positive versus negative 0.011 2.202 1.199–4.043 0.029 2.226 1.083–4.574
 pT stage 0.041 0.031
 pT2 versus pT1 0.030 2.284 1.081–4.826 0.045 2.552 1.020–6.386
 pT3 versus pT1 0.019 3.395 1.218–9.466 0.009 4.635 1.457–14.745
 pN stage 0.013 0.033
 pN1 versus pN0 0.003 2.887 1.419–5.873 0.052 2.303 0.992–5.343
 pN2 versus pN0 0.005 3.231 1.433–7.289 0.005 3.770 1.499–9.477
 pN3 versus pN0 0.107 2.640 0.811–8.589 0.051 3.759 0.994–14.221
 WC: WC ≥ 80 cm versus WC < 80 cm 0.046 1.759 1.009–3.065 0.014 2.297 1.184–4.456
Model 3: WC ≥ 80 cm + BMI ≥ 25 kg/m2 as a  
covariate into Cox regression model
 LVI: positive versus negative 0.011 2.207 1.203–4.051 0.037 2.119 1.045–4.294
 pT stage 0.041 0.033
 pT2:pT1 0.031 2.280 1.080–4.814 0.050 2.496 1.001–6.225
 pT3:pT1 0.019 3.394 1.221–9.439 0.010 4.565 1.439–14.488
 pN stage 0.017 0.027
 pN1:pN0 0.004 2.816 1.384–5.730 0.049 2.306 1.002–5.307
 pN2:pN0 0.005 3.159 1.403–7.115 0.004 3.810 1.532–9.476
 pN3:pN0 0.115 2.576 0.793–8.366 0.045 3.850 1.029–14.413
 WC + BMI: WC ≥ 80 cm and BMI ≥ 25 kg/m2  
versus WC < 80 cm or BMI < 25 kg/m2
0.031 1.845 1.059–3.212 0.010 2.377 1.230–4.593
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tall and strong women as obesity, although which was 
rarely observed in Chinese women. The implementation 
of BMI could distinguish TNBC with poorer prognosis 
even better.
A recent Spanish study pointed out that almost half of 
the obese population were metabolically healthy obese 
phenotype (Goday et  al. 2016). But central obesity is a 
key factor in metabolic syndrome, which is linked to the 
development of diabetes and cardiovascular disease and 
is also closely related with the development of breast can-
cer, especially TNBC (Davis and Kaklamani 2012; Maiti 
et  al. 2010). Systematic reviews indicated that central 
obesity added 79 % risk of breast cancer among premen-
opausal women and 50 % among postmenopausal women 
(Connolly et  al. 2002; Harvie et  al. 2003). And central 
obesity was associated with poorer outcome of breast 
cancer as well (Abrahamson et al. 2006).
Central obesity is characterized by the accumulation 
of visceral fat and WC is a correlate of the amounts of 
visceral fat. There were apparent differences between 
visceral fat and subcutaneous fat with regard to recep-
tor distribution, factors secreted by adipose tissue and 
enzyme activity in adipose cell. Compared with sub-
cutaneous fat, visceral fat have more blood supply and 
nerve distribution and are more likely to accumulate and 
decompose. Visceral fat is more metabolically active.
General obesity is linked to elevated levels of estro-
gen among post-menopausal women. The correlation 
between general obesity and poorer prognosis of breast 
cancer may be mediated by increased circulating estro-
gen levels from excess adiposity through aromatase 
activity and reduced levels of sex hormone-binding 
globulins (Rose and Vona-Davis 2009). Such mechanism 
is more common in postmenopausal obesity patients 
with positive hormone receptor. In contrast, the main 
mechanism of central obesity promoting TNBC pro-
gression is the disturbance of the ‘insulin-leptin-
adiponectin’ axis. Central obesity is an independent 
predictor of insulin resistance (Seidell et  al. 1990) and 
higher levels of free insulin-like growth factor-1 (IGF-1) 
(Lukanova et  al. 2001) compared with general obesity. 
Increased level of insulin and IGF-1 in central obesity 
were mitogenic agents and promoted breast cancer cell 
proliferation directly (Azrad and Demark-Wahnefried 
2014; Demark-Wahnefried et al. 2012). They could also 
accelerate tumor cell growth and migration by activat-
ing tumor neovascularization (Azrad and Demark-Wah-
nefried 2014). Leptin and adiponectin are both obesity 
related regulatory proteins secreted by adipose tissue. 
Leptin increases in obesity. It could enhance IGF-1 
receptor activity and promote TNBC cell proliferation 
and migration. It could also promote survival of can-
cer stem cells in  vivo, consequently promoting breast 
cancer (Zheng et  al. 2013; Oh et  al. 2011). Meanwhile, 
the level of adiponectin is low in obese patients. Adi-
ponectin is the intrinsic insulin sensitizer and plays an 
antitumor effect opposite to leptin. Adiponectin could 
inhibit hormone receptor negative breast cancer cell 
proliferation and induce apoptosis through various sig-
nal transduction pathways (Jardé et  al. 2011). Moreo-
ver, the abundant of inflammation cytokines secreted 
by activated macrophages in the adipose tissue, such as 
TNFα, IL-6, etc., constitutes tumor microenvironment, 
which promotes tumor cell migration and invasion 
(Howe et al. 2013).
It should be noted that our study has some limitations, 
including the retrospective nature of the study design, 
relatively small sample size, short follow-up duration, and 
lack of information on longitudinal change in BMI after 
breast cancer diagnosis which is known to be of prognos-
tic value (Kroenke et al. 2005; Demark-Wahnefried et al. 
2001).
Conclusion
In conclusion, this single-institution study indicated that 
central obesity, especially with high BMI, was an inde-
pendent prognostic factor of OS or DFS in patients with 
TNBC. It was the first study focusing on the association 
between central obesity and TNBC outcome. While the 
interest pertaining to the association between TNBC 
outcomes and obesity should be warranted in larger pro-
spective studies, TNBC patients should be counseled on 
maintaining a healthy weight as a manner of treatment.
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